Combined Modality Trials in Unresectable Stage III Non-Small Cell Lung Cancer: The Cancer and Leukemia Group B Experience

2004 Hensing, 2001, Chemoradiotherapy for stage IIIA,B non-small cell lung cancer, 291 Pfister, 2004, American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline, J Clin Oncol, 22, 10.1200/JCO.2004.09.053 Dillman, 1990, A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer, N Engl J Med, 323, 940, 10.1056/NEJM199010043231403 Dillman, 1996, Improved survival in stage III non-small cell lung cancer, J Natl Cancer Inst, 88, 1210, 10.1093/jnci/88.17.1210 Sause, 1995, Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588, J Natl Cancer Inst, 87, 198, 10.1093/jnci/87.3.198 Le Chevalier, 1992, Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma, J Natl Cancer Inst, 84, 58, 10.1093/jnci/84.1.58 Cullen, 1999, Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer, J Clin Oncol, 17, 3188, 10.1200/JCO.1999.17.10.3188 Clamon, 1994, A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer, Cancer Invest, 12, 273, 10.3109/07357909409023025 Clamon, 1999, Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer, J Clin Oncol, 17, 4, 10.1200/JCO.1999.17.1.4 Vokes, 2002, Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer, J Clin Oncol, 20, 4191, 10.1200/JCO.2002.03.054 Akerley, 2000, Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 19, 490a Vokes, 2004, Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 23, 616 Socinski, 2004, Combined modality trials of the Cancer and Leukemia Group B in stage III non-small lung cancer, Ann Oncol, 15, 1033, 10.1093/annonc/mdh282 Shepherd, 2004, A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial, Proc Am Soc Clin Oncol, 22, 622s Bonner, 2004, Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck, Proc Am Soc Clin Oncol, 22, 14S Ready, 2004, Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 23, 632 Vokes, 2003, A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small cell lung cancer or esophageal cancer, Lung Cancer, 41, S89, 10.1016/S0169-5002(03)91966-0